Ustekinumab: The “New Kid on the Block” in the Treatment of Psoriatic Arthritis

Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial

(2015) Arthur Kavanaugh et al.   ARTHRITIS CARE & RESEARCH

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis

(2015) Robert E. Kalb et al.   JAMA Dermatology

Psoriatic arthritis: latest treatments and their place in therapy

(2015) Eun Jin Kang et al.   Therapeutic Advances in Chronic Disease

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Ten-Year Drug Survival of Anti-TNF Agents in the Treatment of Inflammatory Arthritides

(2014) Martina Biggioggero et al.   DRUG DEVELOPMENT RESEARCH

Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis

(2014) Joshua E Weitz et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing

(2014) David T Felson et al.   ARTHRITIS RESEARCH & THERAPY

Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials

(2013) Radjiv Goulabchand et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

(2013) Iain B McInnes et al.   LANCET

Psoriatic Arthritis

(2012) M. S. Day et al.   JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS

Psoriatic arthritis: update on pathophysiology, assessment and management

(2011) P. J. Mease   ANNALS OF THE RHEUMATIC DISEASES

The early phase of psoriatic arthritis

(2011) D. McGonagle et al.   ANNALS OF THE RHEUMATIC DISEASES

Role of Th17 cells in human autoimmune arthritis

(2010) Jan Leipe et al.   ARTHRITIS AND RHEUMATISM

Ustekinumab

(2010) Oya Cingoz   mAbs

The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis

(2009) Antonella Di Cesare et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET